Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Up 7,330.0% in December

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 148,600 shares, an increase of 7,330.0% from the November 30th total of 2,000 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average daily volume of 46,900 shares, the short-interest ratio is presently 3.2 days.

Alterity Therapeutics Price Performance

Shares of ATHE stock traded up $0.50 during trading hours on Thursday, hitting $2.95. 70,273 shares of the company’s stock were exchanged, compared to its average volume of 50,163. The stock’s 50-day moving average is $1.52 and its 200-day moving average is $1.53. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $3.19.

Analyst Ratings Changes

Separately, Maxim Group initiated coverage on Alterity Therapeutics in a report on Thursday, December 12th. They issued a “buy” rating and a $8.00 target price on the stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.